96
- Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during preg-
nancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203–9. - Bush MC, Patel S, Lapinski RH, et al. Perinatal outcomes in inflammatory bowel disease.
J Matern Fetal Neonatal Med. 2004;15:237–41. - Bröms G, Granath F, Linder M, et al. Birth outcomes in women with inflammatory bowel
disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20:1091–8. - Nørgård B, Hundborg H, Jacobsen BA, et al. Disease activity in pregnant women with
Crohn’s disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol.
2007;102:1947–54. - Nørgård B, Fonager K, Sorensen HT, et al. Birth outcomes of women with ulcerative colitis: a
nationwide Danish cohort study. Am J Gastroenterol. 2000;95:3165–70. - Stephansson O, Larssen H, Pedersen L, et al. Congenital anomalies and other birth outcomes
in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel
Dis. 2011;17:795–801. - Food and Drug Administration. Content and format of labeling for human prescription drug
and biological products; requirements for pregnancy and lactation labeling [Federal Register
Web site]. Available at: http://federalregister.gov/a/2014-28241. 2014. Accessed 20 July 2016. - Bossuyt P, Vermeire S. Treat to target in inflammatory bowel disease. Curr Treat Options
Gastroenterol. 2016;14:61–72. - Brambell FWR. The passive immunity of the young mammal. Biol Rev. 1958;33:485–531.
- Wood WG, Fricke H, von Klitzing L, et al. Solid phase antigen luminescent immunoassays
(SPALT) for the determination of insulin, insulin antibodies and gentamicin levels in human
serum. J Clin Chem Clin Biochem. 1982;20:825–31. - Malek A, Sager R, Schneider H. Maternal-fetal transport of immunoglobulin G and its sub-
classes during the third trimester of human pregnancy. Am J Reprod Immunol. 1994;32:8–14. - Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21:3365–9.
- Palmeira P, Quinello C, Silveriera-Lessa AL, et al. IgG placental transfer in healthy and patho-
logical pregnancies. Clin Dev Immunol. 2012;2012:1–13. - Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroen-
terologists who prescribe therapeutic monoclonal antibodies to women during conception and
pregnancy. Am J Gastroenterol. 2009;104:228–33. - Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental
transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol.
2006;4:1255–8. - Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis fac-
tor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol.
2013;11:286–92. - Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor
therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Clin Gastroenterol Hepatol. 2013;11:318–21. - de Lima A, Zelinkova Z, van der Ent C, et al. Tailored anti-TNF therapy during pregnancy in
patients with IBD: maternal and fetal safety. Gut. 2016;65(8):1261–8. - Julsgaard M, Christensen L, Gibson PR, et al. Concentrations of adalimumab and infliximab
in mothers and newborns, and effects on infection. Gastroenterology. 2016;151:110–9. - Julsgaard M, Brown S, Gibson P, Bell S. Adalimumab levels in an infant. J Crohns Colitis.
2013;7:597–8. - Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following
maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053–8. - van der Woude CJ, Kolacek S, Dotan I, et al. European evidence-based consensus on reproduc-
tion in inflammatory bowel disease. J Crohns Colitis. 2010;4:493–510. - Nguyen GC, Seow CH, Maxwell C, et al. The Toronto consensus statements for the manage-
ment of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150:734–57. - Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving inflix-
imab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol.
2004;99:2385–92.
J.K.J. Gaidos and S.V. Kane